Suchergebnisse - "Shi, Yuankai"

PubPharm (19)

1

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer : a phase Ib study

enthalten in: BMC cancer | 2023

von Hu, X. | Cui, X. | Wang, Z. | +16

2

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer : a multicenter, open-label, first-in-human phase 1 study

enthalten in: BMC medicine | 2022

von Xing, P. | Zhao, Q. | Zhang, L. | +5

3

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer : a phase I dose-escalation and dose-expansion study

enthalten in: BMC cancer | 2022

von Zhang, W. | Han, X. | Yang, L. | +5

4

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation : A Phase 1 Dose-Escalation and Dose-Expansion Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Zhao, Y. | Yang, S. | +19

5

A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Lin, L. | Pan, H. | Li, X. | +13

6

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer : a phase 1 dose-escalation and dose-expansion trial

enthalten in: Signal transduction and targeted therapy | 2022

von Shi, Y. | Fang, J. | Hao, X. | +26

7

Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study

enthalten in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2021

von Cui, X. | Wang, S. | Gao, H. | +5

8

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib : Results from ASCEND-6

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Wu, Y. | Shi, Y. | Tan, D. | +11

9

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Shi, Y. | Zhang, S. | Hu, X. | +16

CommentIn: J Thorac Oncol. 2020 Jun;15(6):881-883. - PMID 32471561

10

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Yang, J. | Dong, L. | Yang, S. | +14